Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303990 | 0.86 | GRM2 (0.32) | GRM2GRM3GRM4CYP1A2ALOX15 | |
| SCHEMBL2433838 | 0.81 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL2433841 | 0.81 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL2433836 | 0.81 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL16237715 | 0.79 | EPHX2 (0.36) | EPHX2GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL18691840 | 0.77 | EPHX2 (0.35) | EPHX2GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL18199 | 0.77 | TSHR (0.45) | EPHX2GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL25287713 | 0.75 | — | — | |
| SCHEMBL6628367 | 0.75 | APLNR (0.37) | EPHX2GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL102778 | 0.75 | SMN1; SMN2 (0.39) | EPHX2GRM2GRM3GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008132128-A2 | SYNTHESIS OF A PHARMACEUTICALLY ACTIVE COMPOUND | Solvay (Société Anonyme) (BE) | 2008-11-06 | — | — | WO | claimed |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-08-07 | — | — | US | disclosed |
| US-12286434-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250109139-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-114213310-B | Indoline compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-02-23 | — | — | CN | disclosed |
| US-20230391781-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2008026986-A1 | A PROCESS FOR PRODUCING [(4,4- DIF LUOROCYCLOHEXYL) METHYL] AMINE | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2006064340-A2 | PROCESS FOR THE PREPARATION OF N-ACYL BETA-AMINOALDEHYDES | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1526134-A2 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | disclosed |
| EP-1284974-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6667314-B2 | For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis | PFIZER, INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1284974-A2 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020013337-A1 | Tropane derivatives useful in therapy | PHIVCO-1 LLC | 2002-01-31 | — | — | US | disclosed |
| WO-2001090106-A2 | TRYASOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391781-A1 | MALT1 MODULATORS AND USES THEREOF | MALT1, SQSTM1, PPP1R10 | EPHX2 4423/4885GRM2 2545/4885GRM3 3417/4885 |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | SAMHD1, IRF3, SLC34A1 | EPHX2 3618/4885GRM2 4864/4885GRM3 4858/4885 |
| US-20250109139-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | PARK7, HADH, BDNF | EPHX2 2676/4885GRM2 1486/4885GRM3 2758/4885 |
| US-20020013337-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | EPHX2 2612/4885GRM2 2030/4885GRM3 830/4885 |
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | EPHX2 2612/4885GRM2 2030/4885GRM3 830/4885 |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ZC3HAV1, GTF3C1, ODC1 | EPHX2 4048/4885GRM2 3840/4885GRM3 2541/4885 |
| US-12286434-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | EPHX2 3104/4885GRM2 1025/4885GRM3 855/4885 |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, REV1, RTF2 | EPHX2 4195/4885GRM2 4862/4885GRM3 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.